Search Results
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
improve gastrointestinal tolerability and long-term treatment adherence. Similarly, ALLYDONE transdermal donepezil patches provide an alternative drug delivery option designed to improve compliance, particularly among elderly patients. In addition, REXULTI (brexpiprazole) has broadened
More news about: DelveInsight Business Research, LLP
Aug 06, 2026, 10:30 ET Multiomics Market worth $5.70 billion by 2031 - Exclusive Report by MarketsandMarkets™
medicine and biopharmaceutical research, and rising adoption of genomics, transcriptomics, proteomics, epigenomics, and spatial omics technologies across drug discovery, biomarker identification, disease research, clinical research, and translational applications.North America accounted for the largest
More news about: MarketsandMarkets
Aug 06, 2026, 09:30 ET Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
tests, today announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration ("FDA") for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument*. The submission
More news about: Co-Diagnostics
Aug 06, 2026, 09:15 ET CellCarta Adds Tempus to CDx Commercialization Lab Network
analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X.Media ContactsStéphanie
More news about: CellCarta
Aug 06, 2026, 09:06 ET Largest, Longest Real-World Study of Migraine in U.S. Veterans Finds that Nerivio® Helps Patients Successfully Skip Prescribed Migraine Medications in 3-out-of-4 of Their Migraine Attacks
pain-inhibitory pathways through Conditioned Pain Modulation (CPM), delivering targeted, drug-free relief. Cleared for patients aged 8 and older, it delivers patented electrical pulses without needles, systemic side effects, or drug interactions. Controlled through a smartphone app, Nerivio enables targeted, on-demand
More news about: Theranica
Aug 06, 2026, 08:30 ET Navigating the Shift from Animal Testing to NAMs in Drug Development, Upcoming Webinar Hosted by Xtalks
and discuss near- and long-term implications for drug development programs. The session will conclude with examples of reduced animal testing paradigms and the integration of NAMs and Model-Informed Drug Development (MIDD) approaches into sponsor drug development programs.For organizations planning
More news about: Xtalks
Aug 06, 2026, 08:30 ET The9 Expands Brand Partnership Network Across Southeast Asia
continues to explore emerging opportunities across AI-empowered industries and the broader digital ecosystem, including an equity stake in AI-driven drug discovery company NYB, building a multi-engine business positioned at the frontier of AI and the new economy, reshaping how value is created and shared.
More news about: The9 Limited
Aug 06, 2026, 08:30 ET Roche expands cyclospora testing portfolio to support U.S. public health response
Cyclospora Outbreak Linked to Iceberg Lettuce in 9 States. Accessed July 24, 2026.U.S. Food and Drug Administration.
More news about: ROCHE DIAGNOSTICS CORPORATION
Aug 06, 2026, 08:30 ET Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
More news about: Caris Life Sciences
Aug 06, 2026, 08:05 ET IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
post-marketing "ChoICE ," study (the "ChoICE Study"), for ProSense® in the local treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across multiple U.S. sites, gathering
More news about: IceCure Medical
Aug 06, 2026, 08:00 ET Phoebe Spotlights 340B Program in First-of-its-Kind Rural Health Report
spotlighting healthcare challenges and solutions in underserved rural areas like southwest Georgia. The first edition takes a look at Phoebe's 340B drug program and the range of services it helps fund to broaden access to care for vulnerable patients.
More news about: Phoebe Putney Health System
Aug 06, 2026, 08:00 ET Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure
More news about: Edgewise Therapeutics
Aug 06, 2026, 08:00 ET Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights."The
More news about: Whitehawk Therapeutics, Inc.
Aug 06, 2026, 08:00 ET Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
in the high teens to low twenties as a percentage of Sanofi's global net sales.Sanofi received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its H5 pandemic influenza vaccine candidate (SP0335) utilizing Matrix-M®.A growing body of scientific
More news about: Novavax, Inc.
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
aims to slow or halt the progression of SOD1-ALS.RAG-17 has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) and been selected for the CARE Program of the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), which facilitates
More news about: Ractigen Therapeutics
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
ROS1-positive non-small cell lung cancer (ROS1+ NSCLC).In May 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for IBTROZI with updated efficacy data in TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC, with a target
More news about: Nuvation Bio, Inc.
Aug 06, 2026, 07:30 ET ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial
More news about: ADC Therapeutics SA
Aug 06, 2026, 07:15 ET Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston
the Company's peptide healthcare platform following the U.S. Food and Drug Administration's recent advisory committee recommendations related to certain compounded peptide substances.Maintained a strong cash position to
More news about: Hydreight Technologies Inc.
Aug 06, 2026, 07:00 ET Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
of 2025, primarily driven by strong growth in international markets.In July 2026, Insmed submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in newly diagnosed patients with MAC lung disease. Similarly, Insmed plans to review the Phase
More news about: Insmed Incorporated
Aug 06, 2026, 07:00 ET Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug developmentNEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ -- Biohaven
More news about: Biohaven Ltd.
Aug 06, 2026, 07:00 ET Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
efficiency of the Sphere-9 catheter."Additionally, in recognition of the critical unmet need for ventricular arrhythmia treatments, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of ventricular arrhythmias, which provides
More news about: Medtronic plc
Aug 06, 2026, 06:59 ET Viatris Reports Second-Quarter 2026 Financial Results
announced that the U.S. Food and Drug Administration (FDA) approved Gwyn LoTM (norelgestromin and ethinyl estradiol transdermal system), a new combined hormonal contraceptive
More news about: Viatris Inc.
Aug 06, 2026, 05:15 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 06, 2026, 05:14 ET Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance
Taiwan Food and Drug Administration (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the U.S. Food and Drug Administration
More news about: Senhwa Biosciences, Inc.
Aug 06, 2026, 04:10 ET Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
Therapeutics, Chief Executive Officer of Kunming Biomed International, and Director of Translational Medicine at Sanofi. Throughout his career, he has led drug discovery, translational pharmacology, and early clinical development programs across biotechnology companies, multinational
More news about: Harbour BioMed